Page 2 - Poster Presentations News Today

I-Mab (Nasdaq: IMAB) (the "Company"), a global biotechnology company focused on bringing highly differentiated medicines to patients around the world through the discovery, development, and commercialization of novel immunotherapies and biologics, today announced that two poster presentations featuring preclinical data on givastomig (also known as TJ-CD4B/ABL111) and TJ-L14B/ABL503, the Company's 4-1BB-targeting bispecific antibody assets, will be reported at the 38th Society for ...

November 1, 2023 News Release BioPorto Announces Two Poster Presentations at ASN Kidney Week 2023 Conference COPENHAGEN, Denmark and BOSTON, MA, USA, November 1, 2023, (GLOBE NEWSWIRE) -- BioPorto A/S (BioPorto or Company) (CPH:BIOPOR), an in vitro diagnostics company focused on empowering the early detection of Acute Kidney Injury (AKI), announced today that, that it will present two poster presentations at the upcoming American Society of Nephrology (ASN) Kidney Week 2023. Both poster presenta

Long-term clinical trial and real-world data illustrate VYVGART® drives consistent, repeatable and clinically meaningful responses, including minimal symptom expression in generalized myasthenia...

Long-term clinical trial and real-world data illustrate VYVGART® drives consistent, repeatable and clinically meaningful responses, including mini...

/PRNewswire/ -- Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company"), a clinical-stage biopharmaceutical company focused on discovering and...

WILMINGTON, Del. and BOSTON, Oct. 14, 2023 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (“Prelude”) (Nasdaq: PRLD), a clinical-stage precision...

WILMINGTON, Del. and BOSTON, Oct. 14, 2023 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (“Prelude”) (Nasdaq: PRLD), a clinical-stage precision oncology company, announces multiple clinical and preclinical posters at the AACR-NCI-EORTC

-- High neutralizing antibody responses sustained through at least 12 months, highlighting potential for durable clinical protection -- -- T cell responses to Spike plus other viral targets observed...

-- High neutralizing antibody responses sustained through at least 12 months, highlighting potential for durable clinical protection -- -- T cell responses to Spike plus other viral targets observed...

CSL Seqirus to Present at 9th ESWI Conference on the Burden of Influenza and Impact of Vaccination on Public Health SUMMIT, N.J., September 15, 2023 --...